NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis $16.14 -0.08 (-0.49%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$16.14 0.00 (0.00%) As of 08/29/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AxoGen Stock (NASDAQ:AXGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AxoGen alerts:Sign Up Key Stats Today's Range$15.88▼$16.4750-Day Range$9.79▼$16.2652-Week Range$9.22▼$21.00Volume1.94 million shsAverage Volume1.72 million shsMarket Capitalization$742.60 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingBuy Company Overview AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida. Read More AxoGen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreAXGN MarketRank™: AxoGen scored higher than 49% of companies evaluated by MarketBeat, and ranked 583rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAxoGen has received no research coverage in the past 90 days.Read more about AxoGen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.29) to ($0.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -161.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -161.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 6.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AxoGen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.17% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AxoGen has recently increased by 32.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.17% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AxoGen has recently increased by 32.69%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.84 News SentimentAxoGen has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for AxoGen this week, compared to 4 articles on an average week.Search Interest6 people have searched for AXGN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.78% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AxoGen's insider trading history. Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AXGN Stock News HeadlinesFDA Extends Review for AxoGen’s Avance Nerve GraftAugust 27 at 5:13 PM | theglobeandmail.comAxogen, Inc. to Participate in Multiple Upcoming Investor ConferencesAugust 27 at 5:13 PM | markets.businessinsider.comAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.August 30 at 2:00 AM | Paradigm Press (Ad)Lake Street Reaffirms Their Buy Rating on AxoGen (AXGN)August 27 at 4:41 AM | theglobeandmail.comRaymond James Sticks to Their Buy Rating for AxoGen (AXGN)August 27 at 4:41 AM | theglobeandmail.comFDA Pushes Back Axogen Avance Nerve Graft Decision By 3 MonthsAugust 25, 2025 | uk.finance.yahoo.comAxogen stock falls after FDA extends review timeline for nerve graftAugust 25, 2025 | za.investing.comWhy Axogen Stock, Up 76% Over The Last Two Months, Just PlummetedAugust 25, 2025 | msn.comSee More Headlines AXGN Stock Analysis - Frequently Asked Questions How have AXGN shares performed this year? AxoGen's stock was trading at $16.48 at the beginning of the year. Since then, AXGN shares have decreased by 2.1% and is now trading at $16.14. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The medical equipment provider had revenue of $31.20 million for the quarter, compared to analysts' expectations of $34.65 million. AxoGen had a negative trailing twelve-month return on equity of 4.43% and a negative net margin of 2.29%. Who are AxoGen's major shareholders? Top institutional investors of AxoGen include First Light Asset Management LLC (9.84%), Balyasny Asset Management L.P. (4.20%), Soleus Capital Management L.P. (3.17%) and Wasatch Advisors LP (3.12%). Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Guido J Neels, Peter J Mariani, Michael Patrick Donovan, Joseph A Tyndall and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings11/02/2021Today8/30/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXGN CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees450Year Founded2002Price Target and Rating Average Price Target for AxoGen$26.00 High Price Target$30.00 Low Price Target$24.00 Potential Upside/Downside+61.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.96 million Net Margins-2.29% Pretax Margin-2.29% Return on Equity-4.43% Return on Assets-2.34% Debt Debt-to-Equity Ratio0.59 Current Ratio4.14 Quick Ratio2.67 Sales & Book Value Annual Sales$187.34 million Price / Sales3.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.44 per share Price / Book6.61Miscellaneous Outstanding Shares46,010,000Free Float44,734,000Market Cap$742.60 million OptionableOptionable Beta1.00 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:AXGN) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.